Research programme: multiple sclerosis gene therapy - TransgeneAlternative Names: Interferon-beta gene therapy - Transgene
Latest Information Update: 07 Mar 2002
At a glance
- Originator Transgene
- Mechanism of Action Interferon beta stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 07 Mar 2002 Discontinued - Preclinical for Multiple sclerosis in France (unspecified route)
- 20 Apr 2000 Preclinical development for Multiple sclerosis in France (Unknown route)